Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Protease-activated receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Protease-activated receptors are a subfamily of related G protein-coupled receptors that are activated by cleavage of part of their extracellular domain. They are highly expressed in platelets, and also on endothelial cells, myocytes and neurons.
PAR (Protease Activated Receptor)-1 antagonist as well as preparation method and application of PAR-1 antagonist
InactiveCN104086501AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseasePharmaceutical drug
The invention relates to the field of thrombotic disease related drugs and particularly relates to a PAR (Protease Activated Receptor)-1 antagonist with a brand new structure as the specification, a preparation method of the PAR-1 antagonist, a pharmaceutical composition containing the PAR-1 antagonist and an application of the PAR-1 antagonist to preparation of drugs for treating thrombotic diseases.
Owner:王佳
PAR (Protease Activated Receptor)-1 antagonist and application thereof
The invention relates to the field of thrombotic disease related drugs and particularly relates to a PAR (Protease Activated Receptor)-1 antagonist with a brand new structure as the specification, wherein a benzene ring at one side of N-morpholinyl is substituted by ethyoxyl, and a benzene ring at the other side of N-morpholinyl is substituted by dimethoxyl. The invention also relates to an application of the PAR-1 antagonist to preparation of drugs for treating thrombotic diseases.
Owner:JILIN BAINIAN HANKE PHARM CO LTD
Injection reagent for cosmetic filling
The invention relates to an injection reagent for cosmetic filling, and the injection reagent comprises the following ingredients in percentage by weight: 13-17% of transforming growth factor -beta, 19-23% of platelet-derived growth factor, 9-12% of epidermal growth factor, 2-4% of fibronectin, 2-4% of vitronectin, 32-38% of protease-activated receptor, 1-2% of interleukin 1beta and 2-6% of cross-linking agent. The injection reagent for cosmetic filling is capable of removing frontal cross striation, crow feet, intercilium wrinkle, nasolabial wrinkle, perioral wrinkle and scars, and is free of untoward effects and safe to use.
Owner:白晋
Protease activity of thrombin inhibits angiogenesis
InactiveUS20050232925A1Easy to produceOrganic active ingredientsSenses disorderUrokinase Plasminogen ActivatorProteinase activity
The present invention features pharmaceutical compositions and methods to inhibit angiogenesis, with implications to cancer therapy. These methods are based on the discovery that activated thrombin has antiangiogenic activity and that this antiangiogenic activity is at least in part, mediated through the activation of a class of thrombin receptors termed, Protease Activated Receptor (PAR). Pharmaceutical compositions and methods are also directed to a class of proteases which mediate this activation, particularly the urokinase plasminogen activator (uPA) polypeptide.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Modulators of protease activated receptors
The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.
Owner:THE UNIV OF QUEENSLAND
Method of treatment and agents useful for same
The present invention relates generally to a method of inducing, stimulating or otherwise facilitating bronchoprotection in humans and animals by modulating bronchial constriction and / or inflammation. The present invention is predicated in part on the identification of receptors in airway epithelium which mediate inhibition of bronchoconstriction and / or inflammation following their activation. More particularly, the present invention identifies that activation of protease activated receptors (PARs) results in relaxation of airway epithelium. Activation of airway epithelium PARs inhibits bronchoconstriction and / or inflammation and thereby mediates bronchoprotection of the airways. The present invention further provides a method for the prophylaxis and treatment of disease conditions in airways such as asthma and bronchitis and further provides methods for the diagnosis and screening of agents useful in the prophylaxis and treatment of airway disease conditions.
Owner:UNIVERSITY OF MELBOURNE
Compounds and methods for treating diseases mediated by protease activated receptors
The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC +1
PAR (Protease Activated Receptor)-1 antagonist and application thereof
ActiveCN104086500AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseaseEthoxidine
The invention relates to the field of thrombotic disease related drugs and particularly relates to a PAR (Protease Activated Receptor)-1 antagonist with a brand new structure as the specification, wherein the benzene ring at one side of N-morpholinyl is substituted by ethyoxyl. The invention also relates to an application of the PAR-1 antagonist to preparation of drugs for treating thrombotic diseases.
Owner:南京望知星医药科技有限公司
Protease-activated receptor 3 and uses thereof
Disclosed are cDNAs and genomic DNAs encoding protease-activated receptor 3 (PAR3) from mouse and human, and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between thrombin and PAR3. Agonists are used as therapeutics to treat wounds, thrombosis, atherosclerosis, restenosis, inflammation, and other thrombin-activated disorders. Antagonists are used as therapeutics to control blood coagulation and thereby treating heart attack and stroke. Antagonists mediate inflammatory and proliferative responses to injury as occur in normal wound healing and variety of diseases including atherosclerosis, restenosis, pulmonary inflammation (ARDS) and glomerulosclerosis. Antibodies specific for a protease-activated receptor 3 (or receptor fragment or analog) and their use as a therapeutic are also disclosed.
Owner:RGT UNIV OF CALIFORNIA
Compounds with terminally-substituted phenyl triazole Schiff base structures and applications of compounds
ActiveCN104086493AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseasePharmaceutical drug
The invention relates to the field of thrombotic disease related drugs, belongs to triazole Schiff base compounds with brand new structures and derivatives of the triazole Schiff base compounds and particularly relates to PAR (Protease Activated Receptor)-1 antagonists with terminally-substituted phenyl triazole Schiff base structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. The substituent groups R1 and R2 are defined as the specification.
Owner:蚌埠格识知识产权运营有限公司
Compounds with terminally-disubstituted triazole Schiff base structure as well as preparation methods and applications of compounds
ActiveCN104086495AGood antithrombotic activityOrganic chemistryBlood disorderDiseasePharmaceutical drug
The invention relates to the field of thrombotic disease related drugs, belongs to triazole Schiff base compounds with brand new structures and derivatives of the triazole Schiff base compounds and particularly relates to PAR (Protease Activated Receptor)-1 antagonists with terminally-disubstituted triazole Schiff base structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. All the substituent groups are defined as the specification.
Owner:JIANGSU BAIJIAN PHARMA TECH CO LTD
Compounds with terminally-disubstituted methyl triazole Schiff base structures as well as preparation methods and applications of compounds
InactiveCN104086494AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseaseMethyl palmoxirate
The invention relates to the field of thrombotic disease related drugs, belongs to triazole Schiff base compounds with brand new structures and derivatives of the triazole Schiff base compounds and particularly relates to PAR (Protease Activated Receptor)-1 antagonists with terminally-disubstituted methyl triazole Schiff base structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. All substituent groups are defined as the specification.
Owner:吴艺雪
Method for treatment of invasive cells
A method for treating metastatic tumor cells of a subject is disclosed. The method comprises administrating to the subject an antisense molecule comprising a nucleotide sequence which is complementary to an RNA sequence of a protease activated receptor (PAR) protein, or an antibody molecule capable of binding to a PAR protein. A method is also described for the treatment of disorders involving the implantation of a placenta in a female subject comprising administrating to the subject the antisense molecule. Also disclosed is the antisense molecule and a pharmaceutical composition comprising it.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT
Par3 mimetic peptides and uses thereof
ActiveUS20190119349A1Polypeptide with localisation/targeting motifNervous disorderPeptideStereochemistry
This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 3 (PAR3) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR3 activity.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Antithrombotic compounds as well as preparation methods and applications of antithrombotic compounds
InactiveCN104086492AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseaseMedicine
The invention belongs to the technical field of medicines and relates to PAR (Protease Activated Receptor)-1 antagonists with structures as shown in the formula I, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases.
Owner:庞庆国
Binding proteins to the human thrombin receptor, par4
PendingCN111670198AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHuman ThrombinReceptor
Owner:MONASH UNIV
Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
InactiveUS20190119300A1Reduce inflammationReduce edemaOrganic chemistryPeptide/protein ingredientsDiseasePROTEASE-ACTIVATED RECEPTOR 4
Owner:VANDERBILT UNIV
Halogenated tetrazole acetophenone compounds as well as preparation methods and applications of halogenated tetrazole acetophenone compounds
ActiveCN104086502AGood antithrombotic activityOrganic active ingredientsOrganic chemistryTetrazolePharmaceutical drug
The invention relates to the field of thrombotic disease related drugs and particularly relates to novel PAR (Protease Activated Receptor)-1 antagonists with halogenated tetrazole acetophenone structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. The group R is defined as the specification.
Owner:珠海优润医药科技有限公司
Antithrombotic compounds as well as preparation methods and applications of antithrombotic compounds
ActiveCN104086496AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseasePharmaceutical drug
The invention belongs to the technical field of medicines and relates to PAR (Protease Activated Receptor)-1 antagonists with structures as shown in the formula I, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases.
Owner:济宁华能制药厂有限公司
Triazole Schiff base compounds as well as preparation methods and applications of triazole Schiff base compounds
ActiveCN104086497AGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseasePharmaceutical drug
The invention relates to the field of thrombotic disease related drugs, belongs to triazole Schiff base compounds with brand new structures and derivatives of the triazole Schiff base compounds and particularly relates to PAR (Protease Activated Receptor)-1 antagonists with triazole Schiff base structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. The compounds have the structures as shown in the specification, wherein all the substituent groups are defined as the specification.
Owner:蚌埠格识知识产权运营有限公司
Compounds and methods for treating diseases mediated by protease activated receptors
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC +1
Halogenated tetrazolium acetophenone compound, its preparation method and use
ActiveCN104086502BGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseaseTetrazole
Owner:珠海优润医药科技有限公司
Modulators of protease activated receptors
Owner:THE UNIV OF QUEENSLAND
Inhibitors of protease activated receptor-2
The present invention relates generally to compounds capable of inhibiting Protease Activated Receptor-2 (PAR2), and uses thereof. More specifically, the present invention relates to inhibitors of PAR2, to their preparation, and to their use in the treatment of diseases and disorders mediated by PAR2 signaling.
Owner:TAKEDA PHARMA CO LTD
Protease Activated Receptor-1 (PAR1) Derived Cytoprotective Polypeptides and Related Methods
ActiveUS20150045283A1High activityReduce mortalityNervous disorderCell receptors/surface-antigens/surface-determinantsArginineApoptosis
The present invention provides novel PAR lderived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and / or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.
Owner:THE SCRIPPS RES INST
Terminal double-substituted triazole Schiff base compound, its preparation method and use
ActiveCN104086495BGood antithrombotic activityOrganic chemistryBlood disorderDiseasePharmaceutical drug
Owner:JIANGSU BAIJIAN PHARMA TECH CO LTD
Par2 mimetic peptides and uses thereof
ActiveUS20190117785A1Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsMedicinePeptide
This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
A kind of antithrombotic compound, its preparation method and application
ActiveCN104086496BGood antithrombotic activityOrganic active ingredientsOrganic chemistryDiseaseAntithrombotic
The invention belongs to the technical field of medicines and relates to PAR (Protease Activated Receptor)-1 antagonists with structures as shown in the formula I, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases.
Owner:济宁华能制药厂有限公司
Whitening composition and its preparation method and use
ActiveCN111012713BReduce dosageIncrease brightnessCosmetic preparationsToilet preparationsBiotechnologyEthyl group
The invention relates to a whitening composition and its preparation method and application. In terms of the mass percentage of the whitening composition, the whitening composition includes the following components: emblica extract: 0.01%-10%, soybean extract: 0.01%-20%, aloin: 0.01%-5% %, ascorbic acid ethyl ether: 0.3% to 5%, nicotinamide: 0.5% to 20%. The whitening composition of the present invention can achieve a balanced whitening effect, that is, it can comprehensively consider all aspects of skin whitening. Specifically, it can start from the process of melanin production, reduce melanin, block the transfer process of melanin, induce and block the protease-activated receptor-2 channel, reduce the phagocytosis of melanosomes by keratinocytes, reduce the transport of melanin, and prevent melanin from entering the cutin Layers and other aspects play a role.
Owner:GUANGZHOU KENENG COSMETICS RES CO LTD +2
PAR2 mimetic peptides and uses thereof
ActiveUS11351264B2Cell receptors/surface-antigens/surface-determinantsHydrolasesPharmaceutical drugPharmacometrics
This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com